CGL
IMDZ

Column Group LP’s Immune Design Corp. IMDZ Stock Holding History

Column Group LP’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$38.6M Hold
3,161,942
– – 100% 1
2015
Q2 		$65.3M Hold
3,161,942
– – 100% 1
2015
Q1 		$66.7M Hold
3,161,942
– – 100% 1
2014
Q4 		$97.1M Buy
+3,161,942
New +$87.9M 100% 1

Other funds holding IMDZ

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Column Group LP's IMDZ Position: Q3 2015 in Review

Column Group LP held its Immune Design Corp. (IMDZ) position steady in Q3 2015 at 3,161,942 shares worth $38.6M. The position accounts for 100% of the portfolio, ranked #1.

Column Group LP first reported a position in IMDZ in Q4 2014 and has held it in 4 quarters since. The position peaked at $97.1M in Q4 2014. 59 funds tracked by Wall St. Rank hold IMDZ as of Q3 2015.

  • Column Group LP held 3,161,942 shares of Immune Design Corp. worth $38.6M as of Q3 2015.
  • Column Group LP left its Immune Design Corp. share count unchanged in Q3 2015.
  • Immune Design Corp. made up 100% of Column Group LP's portfolio in Q3 2015, its #1 holding.
  • Column Group LP first reported a position in Immune Design Corp. in Q4 2014 and has held it in 4 quarters since.
  • Column Group LP's Immune Design Corp. position peaked at $97.1M in Q4 2014.
  • 59 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2015.

Based on Column Group LP's 13F filing for Q3 2015, filed 6 Nov 2015.